Prognostic factors affecting survival and disease-free survival in lymph node-negative breast carcinomas

Journal of Surgical Oncology

Volumn 83, Issue 3, 2003, Pages 167-172

  Kuru, Bekir ^a,b   Camlibel, Mithat ^a   Gulcelik, Mehmet Ali ^a   Alagol, Haluk ^a  

^a Ankara Atatiirk Teaching and Research Hospital   (Turkey)

^b NONE   (Turkey)

Author keywords

Breast carcinoma; Node negative; Prognostic factors

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER INVASION; CANCER SIZE; CANCER SURVIVAL; CLINICAL FEATURE; FEMALE; HAZARD ASSESSMENT; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MEDICAL RECORD; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0038693333     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.10264     Document Type: Article

References (46)

1. Fisher B, Redmond C, Fisher ER, et al., and other contributing NSABP investigators: Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: Patients from NSABP protocol B-06. J Clin Oncol 1988;6:1076-1087.
2. Fisher B, Anderson S, Tan-Chiu E, et al.: Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: Findings from national surgical adjuvant breast and bowel project B-23. J Clin Oncol 2001;19:931-942.
3. Saimuro M, Fukutomi T, Tsuda, et al.: Prognosis of series of 763 consecutive node-negative invasive breast cancer patients without adjuvant therapy: Analysis of clinicopathological prognostic factor. J Surg Oncol 1999;71:101-105.
4. Early breast cancer trialists' collaborative group. Tamoxifen for early breast cancer: An overview of the randomized trials. The Lancet 1998;351:1451-1467.
5. Fisher B, Dignam J, Wolmark N, et al.: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997;89:1673-1682.
6. Goldhirsch A, Glick JH, Gelber RD, et al.: Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Clin Oncol 2001;19:3817-3827.
7. Sigurdson H, Baldetorp B, Borg A, et al.: Indicators of prognosis in node-negative breast cancer. N Engl J Med 1990;322:1045-1053.
8. Aaltomaa S, Lipponen P, Eskelinen M, et al.: Prognostic factors in axillary lymph node-negative breast carcinomas. Eur J Cancer 1991;27:1555-1559.
9. Rosner D, Lane WW: Should all patients with node-negative breast cancer receive adjuvant therapy? Cancer 1991;68:1482-1494.
10. Clayton F: Pathologic correlates of survival in 378 lymph node-negative infiltrating ductal breast carcinomas. Cancer 1991;68:1309-1317.
11. Younes M, Laucirica R: Lack of prognostic significance of histological grade in node-negative invasive breast carcinoma. Clin Cancer Res 1997;3:601-604.
12. Neville AM, Bettelheim R, Gelber RD, et al.: Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. J Clin Oncol 1992;10:696-705.
13. Moorman P, Hamza A, Marks JR, et al.: Prognostic significance of the number of lymph nodes examined in patients with lymph node-negative carcinoma. Cancer 2001;91:2258-2262.
14. Camp RL, Rimm EB, Rimm DL: A high number of tumour free axillary lymph nodes from patients with lymph node negative breast carcinoma is associated with poor outcome. Cancer 2000;88:108-113.
15. Vyas JJ, Desal PB, Sampat MB, et al.: Observations on Indian node-negative breast cancer patients: A multivariate analysis. J Surg Oncol 1989;42:256-263.
16. Reed W, Hannisdal E, Boehler PJ, et al.: The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast cancer. Cancer 2000;88:804-813.
17. Lee AKC, De Lellis RA, Silverman ML, et al.: Prognostic significance of peritumoural lymphatic and blood vessel invasion in node-negative carcinoma of the breast. J Clin Oncol 1990;8:1457-1465.
18. Boyages J, Chua B, Taylor R, et al.: Use of the St. Gallen classification for patients with node-negative breast cancer may lead to overuse of adjuvant chemotherapy. Br J Surg. 2002;89:789-796.
19. Lauria R, Perrone F, Carlomagna C, et al.: The prognostic value of lymphatic and blood vessel invasion in operable breast cancer. Cancer 1995;76:1772-1778.
20. Pinder SE, Ellis IO, Galea M, et al.: Pathological prognostic factors in breast cancer. III. Vascular invasion: Relationship with recurrence and survival in a large study with long-term follow-up. Histopathology 1994;24:41-47.
21. Rosen PP, Groshen S, Kinne DW: Prognosis in T2 N0 M0 Stage I breast carcinoma: A 20-year follow-up study. J Clin Oncol 1991;9:1650-1661.
22. Huseby RA, Ownby HE, Frederick J, et al.: Node-negative breast cancer treated by modified radical mastectomy without adjuvant therapies: Variables associated with disease recurrence and survivorship. J Clin Oncol 1988;6:83-88.
23. Mirza AN, Mirza NQ, Vlastos G, et al.: Prognostic factors in node-negative breast cancer. Ann Surg 2002;235:10-26.
24. Carter CL, Allen C, Henson DE: Relation of tumor size, lymph node status, and survival in 24,740 breast cancer. Cancer 1989;63:181-187.
25. Henson DE, Ries L, Freedman LS, et al.: Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. Cancer 1991;68:2142-2149.
26. Going JJ, Mallon EA, Leake RE, et al.: What the clinician needs from the pathologist: Evidence-based reporting in breast cancer. Eur J Cancer 2002;37(Suppl 7):S5-S17.
27. Pichon MF, Broet P, Magdelenat H, et al.: Prognostic value of steroid receptors after long-term follow-up of 2,257 operable breast cancers. Br J Cancer 1996;73:1545-1551.
28. Nixon AJ, Neuberg D, Hayes DF, et al.: Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol 1994;12:888-894.
29. Schmidt RT, Tsangaris TN, Cheek H: Breast cancer in women under 35 years of age. Am J Surg 1991;162:197-201.
30. Muscoloni G, Villani C, Bedini BV, et al.: Young age is not an ominous prognostic factor in breast cancer patients. Tumori 1987;73:233-235.
31. Aebi S, Gelber S, Castiglione-Gertsch M, et al.: Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? The Lancet 2000;355:1869-1874.
32. Clemente CG, Boracchi P, Andreola S, et al.: Peritumoural lymphatic invasion in patients with node-negative mammary duct carcinoma. Cancer 1992;69:1396-1403.
33. Sosa J, Diener-West M, Gusev Y, et al.: Association between extent of axillary lymph node dissection and survival in patients with stage I breast cancer. Ann Surg Oncol 1998;5:140-149.
34. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer. Experience from a large study with long-term follow-up. Histopathology 1991;19:403-410.
35. Clinical alert from the National Cancer Institute. Breast Cancer Res Treat 1988;12:3-5.
36. O'Reilly SM, Richards MA: Node-negative breast cancer. Adjuvant therapy should probably be reserved for patients at high risk of relapse. BMJ 1990;300:1125-1127.
37. Valagussa P, Bonadonna G, Veronesi U: Patterns of relapse and survival following radical mastectomy. Cancer 1978;41:1170-1178.
38. Merkel DE, Winchester DJ, Goldschmidt RA, et al.: DNA flow cytometry and pathologic grading as prognostic guides in axillary lymph node-negative breast cancer. Cancer 1993:72:1926-1932.
39. Sant M, Gatta G, Micheli A, et al.: Survival and age at diagnosis of breast cancer in a population-based cancer registry. Eur J Cancer 1991;27:981-984.
40. Host H, Lund E: Age as a prognostic factor in breast cancer. Cancer 1986;57:2217-2221.
41. Adami HO, Malker B, Holmberg L, et al.: The relation between survival and age at diagnosis in breast cancer. N Engl J Med 1986;315:559-563.
42. Tsuchiya A, Abe R, Kanno M, et al.: Role of age as a prognostic factor. Surg Today 1997;27:213-216.
43. de la Rochefordiere A, Asselain B, Campana F, et al.: Age as prognostic factor in premenopausal breast carcinoma. The Lancet 1993;341:1039-1043.
44. Walker RA, Lees E, Webb M'B, et al.: Breast carcinoma occurring in young women (<35 years) are different. Br J Cancer 1996;74:1796-1800.
45. Colleoni M, Rotzments N, Robertson C, et al.: Very young women (<35) with operable breast cancer: Features of disease at presentation. Ann Oncol 2002;13:273-279.
46. Kroman N, Jensen MB, Wohlfahrt J, et al.: Factors influencing the effect of age on prognosis in breast cancer: Population based study. BMJ 2000;320:474-478.